N-Nitrosamine in Pharmaceuticals

Waters - Your Analytical Sidekick in Supporting Risk Assessment, Confirmation and Control of N-nitrosamines in Pharmaceuticals.

Ensuring strict control measures are essential to meet regulatory guidelines related to the potential presence of mutagenic impurities in medicines, specifically nitrosamines.

Waters provides accessible LC/MS and MS/MS solutions enabling the development of sensitive, accurate and robust analytical methodologies for the detection and quantification of all types of nitrosamines and their precursors.

From drug development through to manufacturing QC, join forces with Waters as you effectively navigate regulatory guidelines and support both patient safety and the ongoing supply of critical medicines.

Request Pricing Ask us more
  • Overview
  • Literature
  • Application Notes
`

Webinar: How to Avoid the Next Nitrosamine Crisis
Access now.

Mutagenic Impurity Risk Assessment Throughout the Development and Manufacturing Process
Read the full blog here.

The Current Concerns About Genotoxic Impurities Found in Commonly Used Prescription and Over The Counter Pharmaceutical Drugs:
Read the full white paper now.

Method Lifecycle Management: Keep Your Method Fit for Life.
Visit the microsite now.

The Nitrosamine Crisis Podcast - Controlling Risk: An Industry Leader's Perspective
Listen to episode 1

Back To Top Back To Top